---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008925"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:34:08.516300+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat

## Summary
- 240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.
- Denifanstat well tolerated: dry eye syndrome (5.5%) and dry skin (5.2%) most common TEAEs; no denifanstat-related SAEs.
- No AE-related discontinuations; only 1 grade 1 hair thinning resolved without dose change; no deaths.
- All efficacy endpoints (IGA, lesion counts) showed improvements beyond those seen at 12 weeks in the prior Phase 3 trial.
- Ascletis holds China rights; Sagimet retains ex-China rights for denifanstat (FASN inhibitor).

## SEC filing metadata
- accession: 0001104659-26-008925
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/0001104659-26-008925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/tm264534d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008925
- JSON: https://secwatch.observer/filing/0001104659-26-008925.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.